Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2018

Open Access 01-12-2018 | Review

Progress of preoperative and postoperative radiotherapy in gastric cancer

Authors: Nan Zhang, Qian Fei, Jiajia Gu, Li Yin, Xia He

Published in: World Journal of Surgical Oncology | Issue 1/2018

Login to get access

Abstract

Background

Gastric carcinoma, a highly common malignant tumor, is treated mainly by surgery. Meanwhile, radiotherapy is attracting increased attention as a crucial locoregional therapy. However, the application of radiotherapy in gastric carcinoma is still limited and radiation standards remain debatable.

Main body

The use of preoperative radiotherapy for treating gastroesophageal junction cancer has advanced. However, additional phase III clinical trials are needed to further verify the therapeutic value of preoperative radiotherapy for gastric cancer. Patients with D1 or D1 plus lymphadenectomy can benefit from postoperative radiotherapy obviously, and postoperative radiotherapy may be effective for patients with D2 lymphadenectomy with a high N stage. The target volume delineation of preoperative and postoperative radiotherapy should be based on clinical experience and the characteristics of lymphatic drainage.

Conclusions

With the advancement of radiotherapy technology, preoperative and postoperative radiotherapy are becoming increasingly accepted as important auxiliary treatments for gastric cancer.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17:1471.CrossRefPubMed
3.
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMed
4.
Tormo FV, Andreu Martínez FJ, Cardenal MR, Pomares AA. Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer. Clin Transl Oncol. 2006;8:611.CrossRef
5.
Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003;21:223.CrossRefPubMed
6.
Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys. 1998;42:929–34.CrossRefPubMed
7.
Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Rieraknorrenschild J, Langer P, Engenhartcabillic R, Bitzer M, Königsrainer A. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:851.CrossRef
8.
Van HP, Hulshof MC, van Lanschot JJ, Steyerberg EW, Mi VBH, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;367:737–42.
9.
Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol. 2002;80:72–8.CrossRefPubMed
10.
JA A, PF M, N J JM, PW P, PM L, B F RM, R N DSC, LL G. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:2774.CrossRef
11.
Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:1237.CrossRef
12.
Balandraud P, Moutardier V, Giovannini M, Giovannini MH, Lelong B, Guiramand J, Magnin V, Houvenaeghel G, Delpero JR. Locally advanced adenocarcinomas of the gastric cardia: results of pre-operative chemoradiotherapy. Gastroenterol Clin Biol. 2004;28:651.CrossRefPubMed
13.
Klautke G, Foitzik T, Ludwig K, Ketterer P, Klar E, Fietkau R. Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol. 2004;180:695–700.CrossRefPubMed
14.
Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001;8:519.CrossRefPubMed
15.
Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Lind PA, Lindblad M, Ye W, Lundell L, Schuhmacher C, Mauer M. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2015;41:282–94.
16.
Fiorica F, Cartei F, Enea M, Licata A, Cabibbo G, Carau B, Liboni A, Ursino S. The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data. Cancer Treat Rev. 2007;33:729.CrossRefPubMed
17.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Cj VDV, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. J Evid Based Med. 2008;355:11.
18.
Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saintaubert B. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:1715–21.CrossRef
19.
Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:5210–8.CrossRef
20.
21.
22.
Songun I, Putter H, Kranenbarg EM, Sasako M, Cj VDV. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:404–5.CrossRef
23.
Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:2327–33.CrossRef
24.
Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Min GC, Sohn TS, Noh JH. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:268–73.CrossRef
25.
Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim K, Sohn I, Jung SH, Choi MG, Lee JH. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:3130–6.CrossRef
26.
Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, Choi IJ, Kim YJ, Kim DY. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84:585–92.CrossRef
27.
Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, Ji FZ, Zhou XL, Han JH, Wang CS. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2012;104:361–6.CrossRef
28.
Amini A, Jones BL, Stumpf P, Leong S, Lieu CH, Weekes C, Davis SL, Messersmith WA, Purcell WT, Ghosh D, et al. Patterns of care for locally advanced pancreatic adenocarcinoma using the National Cancer Database. Pancreas. 2017;46:904–12.CrossRefPubMedPubMedCentral
29.
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:4387.CrossRef
30.
Datta J, Mcmillan MT, Ruffolo L, Lowenfeld L, Mamtani R, Plastaras JP, Dempsey DT, Karakousis GC, Drebin JA, Fraker DL. Multimodality therapy improves survival in resected early stage gastric cancer in the United States. Ann Surg Oncol. 2016;23:1–10.CrossRef
31.
32.
Shim HJ, Kim KR, Hwang JE, Bae WK, Ryu SY, Park YK, Nam TK, Chung IJ, Cho SH. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. Cancer Chemother Pharmacol. 2016;77:605–12.CrossRefPubMed
33.
Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:330–5.CrossRefPubMed
34.
Pang X, Wei W, Leng W, Chen Q, Xia H, Chen L, Li R. Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35:387–96.CrossRef
35.
Soon YY, Leong CN, Tey JC, Tham IW, Lu JJ. Postoperative chemo-radiotherapy versus chemotherapy for resected gastric cancer: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2014;58:483.PubMed
36.
Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res. 2008;14:82.CrossRefPubMed
37.
Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754.CrossRefPubMedPubMedCentral
38.
Bargielaiparraguirre J, Pradomarchal L, Fernandezfuente M, Gutierrezgonzález A, Morenorubio J, Muñozfernandez M, Sereno M, Sanchezprieto R, Perona R, Sanchezperez I. CHK1 expression in gastric cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. Sci Rep. 2016;6:21519.CrossRef
39.
Matzinger O, Gerber E, Bernstein Z, Maingon P, Haustermans K, Bosset JF, Gulyban A, Poortmans P, Collette L, Kuten A. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol J Eur Soc Therap Radiol Oncol. 2009;92:164–75.CrossRef
40.
Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, van der Sangen MJ, Beukema JC, Rütten H, Spruit PH. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:385.CrossRef
41.
Smalley SR, Gunderson L, Tepper J, Jr MJ, Minsky B, Willett C, Rich T. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys. 2002;52:283–93.CrossRefPubMed
42.
Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol. 2002;12:187.CrossRefPubMed
43.
Nam H, Lim-Do H, Kim S, Kang W, Sohn T, Noh J, Kim Y, Park C, Park C, Ahn Y, Huh S. A new suggestion for the radiation target volume after a subtotal gastrectomy in patients with stomach cancer. Int J Radiat Oncol Biol Phys. 2008;71:448–55.CrossRefPubMed
44.
Ohira M, Toyokawa T, Sakurai K, Kubo N, Tanaka H, Muguruma K, Yashiro M, Onoda N, Hirakawa K. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol. 2016;22:2424.CrossRefPubMedPubMedCentral
45.
Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, Rha SY, Lee CG, Koom WS. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol J Eur Soc Therap Radiol Oncol. 2012;104:367–73.CrossRef
46.
Yoon HI, Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, Rha SY, Kim KH, Koom WS. Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation. Radiother Oncol J Eur Soc Therap Radiol Oncol. 2013;108:72–7.CrossRef
47.
Haijun Y, Qiuji W, Zhenming F, Yong H, Zhengkai L, Conghua X, Yunfeng Z, Yahua Z. A new approach to delineating lymph node target volumes for post-operative radiotherapy in gastric cancer: a phase II trial. Radiother Oncol J Eur Soc Therap Radiol Oncol. 2015;116:245.CrossRef
Metadata
Title
Progress of preoperative and postoperative radiotherapy in gastric cancer
Authors
Nan Zhang
Qian Fei
Jiajia Gu
Li Yin
Xia He
Publication date
01-12-2018
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1490-7

Other articles of this Issue 1/2018

World Journal of Surgical Oncology 1/2018 Go to the issue

Case report

Pregnancy, delivery, and breastfeeding after total gastrectomy for gastric cancer: a case report

Research

Association between the sonographer’s experience and diagnostic performance of IOTA simple rules

Case Report

Garcin syndrome caused by sphenoid bone metastasis of lung cancer: a case study

Research

Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla

Research

Immunohistochemical expression of epidermal growth factor receptor (EGFR) in South Asian head and neck squamous cell carcinoma: association with various risk factors and clinico-pathologic and prognostic parameters

Research

Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma